Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial

Abstract Previous studies have suggested that Helicobacter pylori (H. pylori) infection is associated with nonalcoholic fatty liver disease (NAFLD). The purpose of the present study was to investigate the effect of H. pylori eradication treatment on NAFLD patients. Two hundred NAFLD patients who tes...

Full description

Bibliographic Details
Main Authors: Ying-ying Yu, Yu-ling Tong, Ling-yan Wu, Xin-yan Yu
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-23746-0
_version_ 1811309254585352192
author Ying-ying Yu
Yu-ling Tong
Ling-yan Wu
Xin-yan Yu
author_facet Ying-ying Yu
Yu-ling Tong
Ling-yan Wu
Xin-yan Yu
author_sort Ying-ying Yu
collection DOAJ
description Abstract Previous studies have suggested that Helicobacter pylori (H. pylori) infection is associated with nonalcoholic fatty liver disease (NAFLD). The purpose of the present study was to investigate the effect of H. pylori eradication treatment on NAFLD patients. Two hundred NAFLD patients who tested positive for H. pylori infection were randomized into the H. pylori eradication treatment group or the control group. Metabolic and inflammatory parameters and FibroScan were measured in all subjects at baseline and 1 year after treatment. At 1 year after treatment, the decrease in metabolic indicators, such as fasting blood glucose, glycosylated haemoglobin, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides, body mass index and controlled attenuation parameter values, were more obvious in the treatment group. Moreover, the inflammatory indicators white blood count and high-sensitivity C-reactive protein (hs-CRP) and the inflammatory factors interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α) were also significantly decreased. H. pylori eradication can further reduce the metabolic indices of NAFLD and the degree of liver steatosis. H. pylori infection may participate in the occurrence and development of NAFLD through its influence on inflammatory factors. Thus, checking for the presence of H. pylori infection in patients at risk of NAFLD may be beneficial.
first_indexed 2024-04-13T09:38:59Z
format Article
id doaj.art-85cd71c8656c4c5cb7fa41bc294da7a4
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-13T09:38:59Z
publishDate 2022-11-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-85cd71c8656c4c5cb7fa41bc294da7a42022-12-22T02:52:01ZengNature PortfolioScientific Reports2045-23222022-11-0112111010.1038/s41598-022-23746-0Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trialYing-ying Yu0Yu-ling Tong1Ling-yan Wu2Xin-yan Yu3Department of General Practice, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of General Practice, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of General Practice, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of General Practice, The Second Affiliated Hospital, Zhejiang University School of MedicineAbstract Previous studies have suggested that Helicobacter pylori (H. pylori) infection is associated with nonalcoholic fatty liver disease (NAFLD). The purpose of the present study was to investigate the effect of H. pylori eradication treatment on NAFLD patients. Two hundred NAFLD patients who tested positive for H. pylori infection were randomized into the H. pylori eradication treatment group or the control group. Metabolic and inflammatory parameters and FibroScan were measured in all subjects at baseline and 1 year after treatment. At 1 year after treatment, the decrease in metabolic indicators, such as fasting blood glucose, glycosylated haemoglobin, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides, body mass index and controlled attenuation parameter values, were more obvious in the treatment group. Moreover, the inflammatory indicators white blood count and high-sensitivity C-reactive protein (hs-CRP) and the inflammatory factors interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α) were also significantly decreased. H. pylori eradication can further reduce the metabolic indices of NAFLD and the degree of liver steatosis. H. pylori infection may participate in the occurrence and development of NAFLD through its influence on inflammatory factors. Thus, checking for the presence of H. pylori infection in patients at risk of NAFLD may be beneficial.https://doi.org/10.1038/s41598-022-23746-0
spellingShingle Ying-ying Yu
Yu-ling Tong
Ling-yan Wu
Xin-yan Yu
Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
Scientific Reports
title Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
title_full Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
title_fullStr Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
title_full_unstemmed Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
title_short Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial
title_sort helicobacter pylori infection eradication for nonalcoholic fatty liver disease a randomized controlled trial
url https://doi.org/10.1038/s41598-022-23746-0
work_keys_str_mv AT yingyingyu helicobacterpyloriinfectioneradicationfornonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT yulingtong helicobacterpyloriinfectioneradicationfornonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT lingyanwu helicobacterpyloriinfectioneradicationfornonalcoholicfattyliverdiseasearandomizedcontrolledtrial
AT xinyanyu helicobacterpyloriinfectioneradicationfornonalcoholicfattyliverdiseasearandomizedcontrolledtrial